Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTSG NASDAQ:HRMY NASDAQ:PTCT NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTSGBrightSpring Health Services$58.50$47.64$19.01▼$59.65$11.34B1.713.19 million shs1.45 million shsHRMYHarmony Biosciences$30.15$29.43$25.52▼$40.87$1.75B0.97750,644 shs431,487 shsPTCTPTC Therapeutics$68.81$69.00$43.17▼$87.50$5.71B0.531.58 million shs715,145 shsVERAVera Therapeutics$34.04$39.02$18.76▼$56.05$2.44B0.961.08 million shs448,618 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTSGBrightSpring Health Services0.00%+1.04%+21.47%+46.29%+151.83%HRMYHarmony Biosciences0.00%+0.20%-2.11%+12.21%-11.76%PTCTPTC Therapeutics0.00%-3.72%+0.85%-2.40%+49.81%VERAVera Therapeutics0.00%-8.79%-9.68%-19.07%+73.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTSGBrightSpring Health Services$58.50$47.64$19.01▼$59.65$11.34B1.713.19 million shs1.45 million shsHRMYHarmony Biosciences$30.15$29.43$25.52▼$40.87$1.75B0.97750,644 shs431,487 shsPTCTPTC Therapeutics$68.81$69.00$43.17▼$87.50$5.71B0.531.58 million shs715,145 shsVERAVera Therapeutics$34.04$39.02$18.76▼$56.05$2.44B0.961.08 million shs448,618 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTSGBrightSpring Health Services0.00%+1.04%+21.47%+46.29%+151.83%HRMYHarmony Biosciences0.00%+0.20%-2.11%+12.21%-11.76%PTCTPTC Therapeutics0.00%-3.72%+0.85%-2.40%+49.81%VERAVera Therapeutics0.00%-8.79%-9.68%-19.07%+73.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTSGBrightSpring Health Services 3.12Buy$57.00-2.56% DownsideHRMYHarmony Biosciences 2.27Hold$40.8935.62% UpsidePTCTPTC Therapeutics 2.57Moderate Buy$88.3628.41% UpsideVERAVera Therapeutics 2.75Moderate Buy$79.00132.08% UpsideCurrent Analyst Ratings BreakdownLatest BTSG, PTCT, VERA, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026HRMYHarmony Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026BTSGBrightSpring Health Services BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$70.005/15/2026VERAVera Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$91.005/11/2026PTCTPTC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/8/2026PTCTPTC Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$94.005/8/2026PTCTPTC Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$75.00 ➝ $90.005/8/2026HRMYHarmony Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$25.00 ➝ $29.005/8/2026PTCTPTC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$81.00 ➝ $82.005/8/2026PTCTPTC Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$86.00 ➝ $95.005/6/2026BTSGBrightSpring Health Services Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$48.00 ➝ $62.005/5/2026BTSGBrightSpring Health Services MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$52.00 ➝ $61.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTSGBrightSpring Health Services$12.91B0.88$2.20 per share26.62$10.21 per share5.73HRMYHarmony Biosciences$868.45M2.01$3.18 per share9.48$15.73 per share1.92PTCTPTC Therapeutics$1.73B3.30$8.78 per share7.84($2.18) per share-31.56VERAVera TherapeuticsN/AN/AN/AN/A$6.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTSGBrightSpring Health Services$190.67M$1.4141.4929.400.772.27%14.63%4.41%7/31/2026 (Estimated)HRMYHarmony Biosciences$158.69M$2.4812.168.280.2016.20%17.19%11.99%8/4/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A35.4712.83-22.58%-362.45%-6.76%8/6/2026 (Estimated)VERAVera Therapeutics-$299.61M-$5.54N/AN/AN/AN/A-74.86%-60.18%8/4/2026 (Estimated)Latest BTSG, PTCT, VERA, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026HRMYHarmony Biosciences$0.76$0.55-$0.21$0.55$220.84 million$215.39 million5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/7/2026Q1 2026VERAVera Therapeutics-$1.3284-$1.69-$0.3616-$1.69$0.43 millionN/A5/1/2026Q1 2026BTSGBrightSpring Health Services$0.29$0.39+$0.10$0.67$3.39 billion$3.61 billion2/27/2026Q4 2025BTSGBrightSpring Health Services$0.34$0.33-$0.01$0.35$3.38 billion$3.55 billion2/26/2026Q4 2025VERAVera Therapeutics-$1.34-$1.39-$0.05-$1.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTSGBrightSpring Health ServicesN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTSGBrightSpring Health Services1.241.741.38HRMYHarmony Biosciences0.153.583.56PTCTPTC TherapeuticsN/A2.442.36VERAVera Therapeutics0.1513.6413.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTSGBrightSpring Health ServicesN/AHRMYHarmony Biosciences86.23%PTCTPTC TherapeuticsN/AVERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipBTSGBrightSpring Health Services2.80%HRMYHarmony Biosciences11.00%PTCTPTC Therapeutics5.50%VERAVera Therapeutics15.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTSGBrightSpring Health Services23,500193.92 million188.49 millionOptionableHRMYHarmony Biosciences20057.89 million51.53 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableVERAVera Therapeutics4071.78 million60.37 millionOptionableBTSG, PTCT, VERA, and HRMY HeadlinesRecent News About These CompaniesTimesSquare Capital Management LLC Makes New $12.79 Million Investment in Vera Therapeutics, Inc. $VERAMay 20, 2026 | marketbeat.comUBS Group AG Boosts Position in Vera Therapeutics, Inc. $VERAMay 16, 2026 | marketbeat.comVera Therapeutics (NASDAQ:VERA) CEO Sells $679,690.00 in StockMay 14, 2026 | insidertrades.comVanguard Group Inc. Grows Stake in Vera Therapeutics, Inc. $VERAMay 11, 2026 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of "Moderate Buy" from AnalystsMay 11, 2026 | marketbeat.comThe Bull Case For Vera Therapeutics (VERA) Could Change Following Atacicept’s FDA Priority Review And Ramp-UpMay 11, 2026 | finance.yahoo.comSwedbank AB Increases Stock Holdings in Vera Therapeutics, Inc. $VERAMay 10, 2026 | marketbeat.comVera Therapeutics (VERA) Gets a Buy from LifeSci CapitalMay 8, 2026 | theglobeandmail.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8, 2026 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Misses Expectations By $0.36 EPSMay 7, 2026 | marketbeat.comVera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comVera Therapeutics to Participate in the Bank of America Securities 2026 Health Care ConferenceMay 4, 2026 | globenewswire.comPictet Asset Management Holding SA Cuts Stake in Vera Therapeutics, Inc. $VERAApril 29, 2026 | marketbeat.comVera Therapeutics (VERA) to Release Earnings on TuesdayApril 28, 2026 | marketbeat.comVera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 22,951 SharesApril 16, 2026 | insidertrades.comVera Therapeutics, Inc. Class AApril 11, 2026 | edition.cnn.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 10, 2026 | globenewswire.comIs Vera Therapeutics (VERA) Still Attractive After An 87% One Year Share Price SurgeApril 10, 2026 | finance.yahoo.comThese 5 Biotechs Could Be the Next Big GLP-1 Acquisition TargetApril 1, 2026 | 247wallst.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 27, 2026 | globenewswire.comVera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal OfficerMarch 25, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesViking Therapeutics Faces Timeline Risk—But Upside Could Be HugeBy Chris Markoch | May 1, 2026HIVE Weaponizes Power for an AI PivotBy Jeffrey Neal Johnson | May 19, 2026Viking Sails to All-Time Highs—Fundamentals Signal More to ComeBy Chris Markoch | May 15, 2026Amazon Weaponizes Logistics, Triggering Sector-Wide SelloffBy Jeffrey Neal Johnson | May 5, 2026Powering Up: UGI Banks $685M in Strategic TurnaroundBy Jeffrey Neal Johnson | May 4, 2026BTSG, PTCT, VERA, and HRMY Company DescriptionsBrightSpring Health Services NASDAQ:BTSG$58.50 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$57.75 -0.75 (-1.28%) As of 05/22/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BrightSpring Health Services, Inc. operates a home and community-based healthcare services platform in the United States. The company's platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It serves patients through clinical providers and pharmacists. The company was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. BrightSpring Health Services, Inc. was founded in 1974 and is headquartered in Louisville, Kentucky.Harmony Biosciences NASDAQ:HRMY$30.15 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$30.16 +0.01 (+0.03%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.PTC Therapeutics NASDAQ:PTCT$68.81 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$68.68 -0.13 (-0.19%) As of 05/22/2026 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Vera Therapeutics NASDAQ:VERA$34.04 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$34.11 +0.07 (+0.20%) As of 05/22/2026 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
